Our Team

We’ve brought together commercial leaders, researchers and biotechnology experts that will transform therapeutics development.

AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including:

  • post-surgical pain management
  • cancer
  • other hard-to-reach targets

We’re developing products at the intersection of bio­ma­te­ri­als and pharmaceuticals.

Molecule yellow

Senior Management Team

Dr Mike Cooke v2
Dr. Mike Cooke
Co-Founder & CEO
Biomedical Engineer
Polymer design and drug delivery expert
Dr Molly Shoichet v2
Dr. Molly Shoichet
Co-Founder & Chief Science Officer
Chemical & Biomedical Engineer
Polymer design and drug delivery expert
Mike Foorer v2
Mike Foorer
Vice President Business Development & General Manager
25 years experience in drug delivery & sterile injectable manufacturing

Board of Directors

In addition to co-founders Mike Cooke and Molly Shoichet, our board is made up of the following:

Lu han
Lu Han
Partner, Lumira Ventures
BSc, PhD
Michelle Scarborough v1
Michelle Scarborough
Managing Partner,
Strategic Investments and Women in Technology Fund, BDC
Sara Secall v1
Sara Secall
Partner & Life Sciences Investment Director, Inveready Asset Management
Yinghong Gao
Yinghong Gao
Venture Partner, Viva BioInnovator

Recent News

New study setting the stage for non-opioid analgesic in post-surgical pain management

   Press Release

AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more

AmacaThera Doses First Subjects in Phase 1 Clinical Trial for AmacaGel™ Therapeutic Platform

   Press Release

AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more

AmacaThera’s Lung Cancer Applications Recognized in QuickFire Challenge

   Press Release

AmacaThera has received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma.Read more

Amacathera Logo

AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.

Contact Us

MaRS Centre, West Tower,
661 University Ave Suite 1300,
Toronto, ON M5G 0B7

[email protected]